Charles River Laboratories International Inc. (CRL)
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CRL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.46B
- Forward P/E
- 23.41
- EPS (TTM)
- -$4.80
- Dividend yield
- None
- 52-week range
- 146.20 – 333.30
- Day range
- 294.37 – 305.18
- Volume / Avg
- 1.24M / 940.11K
- Beta
- —
- Shares outstanding
- 48.17M
- Next earnings
- Nov 4, 2026
52-week range
CRL stock today
Charles River Laboratories International (CRL) closed at $300.30 on Oct 7, down 1.53% (-$4.66), versus the S&P 500's 0.22% decline. Shares are 9.9% below their 52-week high of $333.30, set on Oct 6, 2026 and 105.4% above the 52-week low of $146.20, near the top of the past year's range. CRL is up 50.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 76.5%.
Charles River Laboratories International has posted a net loss over the last twelve months (EPS of -$4.80), so its P/E ratio is not meaningful. Charles River Laboratories International's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Charles River Laboratories International
Company profileCharles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Ms. Birgit Girshick
- Headquarters
- Wilmington, MA
- Employees
- 18,300
- IPO year
- 2000
- Website
- criver.com
Financial highlights
Full financialsIn fiscal 2025, Charles River Laboratories International generated $4.02 billion in revenue, down 0.9% from fiscal 2024, its first annual decline since 2024. Charles River Laboratories International reported a net loss of $144.3 million, compared with net income of $22.2 million a year earlier. Operating margin was 0.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Growth | -0.85% | -1.92% | +3.86% | +12.31% | +21.08% |
| Net income | $-144.34M | $22.20M | $474.62M | $486.23M | $390.98M |
| EPS (diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Analyst forecast
ForecastConsensus (18 analysts)
buy
Avg. price target
$305.00+1.57%
- Strong buy 4
- Buy 11
- Hold 2
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $2.97
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-0.03 vs —
CRL news
All CRL news- Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5%NasdaqCRL, HTFL, ILMN, INFU
- Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in FocusNasdaqMSFT, ICE, ACN, PAYX
- Charles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?NasdaqCRL, HCA
- CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?NasdaqCRL, MEDP, IQV
Charles River Laboratories International peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ICLRICON plc | 164.08 | +1.48% | $12.66B | vs CRL |
| MEDPMedpace Holdings Inc. | 604.25 | +0.22% | $16.87B | vs CRL |
| INCYIncyte Corp. | 113.44 | +0.63% | $22.99B | vs CRL |
| ABSIAbsci Corporation | 9.22 | -10.22% | $1.58B | vs CRL |
| OABIOmniAb Inc. | 4.56 | +4.83% | $662.98M | vs CRL |
| NRCNRC Health | 20.19 | +0.55% | $446.59M | vs CRL |
| MXCTMaxCyte Inc. | 1.04 | -4.59% | $107.33M | vs CRL |
| ONMDOneMedNet Corp Class A | 4.91 | -1.21% | $28.60M | vs CRL |
Indexes, lists and sector
Index membership
Charles River Laboratories International stock FAQ
What is Charles River Laboratories International's stock price today?
CRL last traded at $300.30 as of Oct 7, 4:00 PM EDT, down 1.53% on the day. Prices are delayed at least 15 minutes.
When is Charles River Laboratories International's next earnings date?
Charles River Laboratories International is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $2.97.
Is Charles River Laboratories International in the S&P 500?
Yes. Charles River Laboratories International (CRL) is a constituent of the S&P 500 index.
Who is Charles River Laboratories International's CEO?
Ms. Birgit Girshick is the chief executive officer of Charles River Laboratories International Inc., which has about 18,300 employees.
What is the CRL 52-week high?
The 52-week high for CRL is $333.30 and the 52-week low is $146.20. The stock is currently 9.9% below its high.